AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the company expands its work to include the technology first proven in the Covid-19 pandemic.Shares in CanSino rose more than 25 per cent on Wednesday after the company announced the agreement to provide manufacturing services for the Anglo Swedish drugmaker. The companies did not disclose the value of the deal.
阿斯利康(AstraZeneca)与manbetx3.0 制药公司康希诺生物(CanSino Biologics)签署了一项协议，将开发潜在的mRNA疫苗。目前，阿斯利康正在扩大其研发范围，将这种在新冠疫情中首次得到验证的技术纳入其中。
您已阅读13%（555字），剩余87%（3580字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。